Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Dec 1;64(23):3460-3464.
doi: 10.2169/internalmedicine.5028-24. Epub 2025 May 22.

Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification

Takaaki Tanaka  1 , Go Makimoto  1 , Ryohei Sumii  2 , Rika Omote  3 , Yayoi Ando  4 , Kiichiro Ninomiya  5 , Eiki Ichihara  6 , Kadoaki Ohashi  1 , Yoshinobu Maeda  7 , Masahiro Tabata  6
Affiliations
Free article
Case Reports

Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification

Takaaki Tanaka et al. Intern Med. .
Free article

Abstract

This case report describes a 70-year-old female with cancer of unknown primary origin (CUP) who exhibited multiple distant lymph node metastases. Despite conventional chemotherapy (carboplatin and paclitaxel) and immunotherapy (nivolumab), disease progression was noted. Genomic profiling revealed MET amplification, leading to the administration of capmatinib, a selective MET tyrosine kinase inhibitor. The patient experienced substantial tumor reduction with dose adjustments due to adverse effects, indicating the potential efficacy of capmatinib in treating CUP with MET amplification.

Keywords: MET amplification; MET exon 14 skipping; MET inhibitors; cancer of unknown primary; capmatinib.

PubMed Disclaimer

Publication types